APA (7th ed.) Citation

KV, K., NB, M., K, P., JM, V., C, F., FH, V., & S, G. (2023). Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: An open-label, multicentre, proof-of-concept phase 2 trial. The lancet. Gastroenterology & hepatology, 8(12), 1118. https://doi.org/10.1016/S2468-1253(23)00250-9

Chicago Style (17th ed.) Citation

KV, Kowdley, Modi NB, Peltekian K, Vierling JM, Ferris C, Valone FH, and Gupta S. "Rusfertide for the Treatment of Iron Overload in HFE-related Haemochromatosis: An Open-label, Multicentre, Proof-of-concept Phase 2 Trial." The Lancet. Gastroenterology & Hepatology 8, no. 12 (2023): 1118. https://doi.org/10.1016/S2468-1253(23)00250-9.

MLA (9th ed.) Citation

KV, Kowdley, et al. "Rusfertide for the Treatment of Iron Overload in HFE-related Haemochromatosis: An Open-label, Multicentre, Proof-of-concept Phase 2 Trial." The Lancet. Gastroenterology & Hepatology, vol. 8, no. 12, 2023, p. 1118, https://doi.org/10.1016/S2468-1253(23)00250-9.